Løkkegaard, S., Elias, D., Alves, C. L., Bennetzen, M. V., Lænkholm, A., Bak, M., . . . Ditzel, H. J. (2021). MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Nature Portfolio.
Cita Chicago Style (17a ed.)Løkkegaard, Sanne, et al. MCM3 Upregulation Confers Endocrine Resistance in Breast Cancer and Is a Predictive Marker of Diminished Tamoxifen Benefit. Nature Portfolio, 2021.
Cita MLA (8a ed.)Løkkegaard, Sanne, et al. MCM3 Upregulation Confers Endocrine Resistance in Breast Cancer and Is a Predictive Marker of Diminished Tamoxifen Benefit. Nature Portfolio, 2021.
Precaución: Estas citas no son 100% exactas.